新型超长效基础胰岛素类似物的临床应用  

Clinical Application of New Ultra-long-acting Basic Insulin Analogues

作　　者：陈慧[1] CHEN Hui(The Second Hospital of Lanzhou University,Lanzhou Gansu 730030,China)

机构地区：[1]兰州大学第二医院,甘肃兰州730030

出　　处：《药品评价》2023年第6期776-780,共5页Drug Evaluation

摘　　要：基础胰岛素治疗是临床重要的胰岛素治疗方案。生理性的胰岛素分泌相对平稳和持久,为模拟这种分泌特性,实现在达到稳态时具有平稳的、覆盖全天24 h的药代/药效学特性,人们通过改变胰岛素制剂成分及胰岛素分子的氨基酸结构等方法,研发了多种胰岛素制剂。新型超长效基础胰岛素类似物,在起效时间、峰值时间、作用持续时间上,更接近生理性胰岛素分泌模式。本文就新型超长效基础胰岛素的药代动力学和药效学特点、降糖疗效和安全性,以及临床替代治疗方案等内容进行分析,以期为这类药物的临床应用提供一定的参考。Basal insulin therapy plays a pivotal role in the treatment of patients with diabetes mellitus.There have been ongoing attempts to produce formulations with more prolonged and/or flatter pharmacokinetic(PK)and pharmacodynamic(PD)profiles over 24 h that better mimic the low and constant physiological basal insulin secretion seen in the fasting state in healthy subjects.The ultra-long-acting insulin analogue are more closely resembles physiological insulin secretion in the timing of onset,peak,and duration of action.It is widely used in clinical practice with providing longer and flatter action profiles,which come closer to the ideal of creating a peakless basal insulin.This article reviews the PK/PD data,clinical efficacy and safety,and therapeutic regimens of the ultra-long-acting insulin analogue,aiming to provide evidence-based insights into their clinical use.

关 键 词：胰岛素 长效 糖尿病 德谷胰岛素 甘精胰岛素 

分 类 号：R977.15[医药卫生—药品]